Methyl 1-[(2'-cyanobiphenyl-4-yl)-methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate 98%

We are an integrated pharmaceutical company with a strong portfolio of niche formulations, APIs and advanced intermediates Viyash and its subsidiaries operate 10 API / Intermediate facilities with a combined capacity ~2000 KL and diversified capabilities in every aspect - small / large volume, potent / non-potent, regulated / semi-regulated markets.

In addition, we also operate one formulation manufacturing facility in New Jersey, USA with a capacity of ~ 1.2 Bn units.

Leading from the front and staying honest about our origin mission, the two qualities associated with the Vedic interpretation of “Viyash”, are the propellers of success for any pharmaceutical initiative. We work professionally every day with a single-minded intent to build trust and honest relationships with our community and with our customers.

Our robust API and Formulations R&D infrastructure with a combined strength of over 200 scientists offers expertise across several technologies and complex reactions.  Top that with a diversified mix of portfolio across multiple therapy areas such as ARV, CV, CNS, Analgesics, Antibiotics, Antihistamines, Diabetes, GI, Anticoagulants, Oncology etc., and you get the perfect Viyash potion.